Evidence mapPaperPMID 39201436Full record

ReviewInternational journal of molecular sciences2024

Benefits and Challenges of Drug-Coated Balloons in Peripheral Artery Disease: From Molecular Mechanisms to Clinical Practice.

Dan-Alexandru Tataru, Florin-Leontin Lazar, Horea-Laurentiu Onea, Calin Homorodean, Mihai-Claudiu Ober, Maria Olinic, Mihail Spinu, Dan-Mircea Olinic

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Drug-Coated Balloons: Recent Evidence and Upcoming Novelties.Journal of cardiovascular development and disease · 2025
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dan-Alexandru TataruMedical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", 400006 Cluj-Napoca, Romania.ORCID 0000-0002-4612-6405
Florin-Leontin LazarMedical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", 400006 Cluj-Napoca, Romania.
Horea-Laurentiu OneaMedical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", 400006 Cluj-Napoca, Romania.ORCID 0000-0002-8819-7690
Calin HomorodeanMedical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", 400006 Cluj-Napoca, Romania.
Mihai-Claudiu OberInterventional Cardiology Department, Cluj County Emergency Hospital, 400006 Cluj-Napoca, Romania.ORCID 0000-0002-6203-0825
Maria OlinicMedical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", 400006 Cluj-Napoca, Romania.
Mihail SpinuMedical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", 400006 Cluj-Napoca, Romania.ORCID 0000-0002-3010-5650
Dan-Mircea OlinicMedical Clinic No. 1, Internal Medicine Department, University of Medicine and Pharmacy "Iuliu Hatieganu", 400006 Cluj-Napoca, Romania.ORCID 0000-0002-1886-9375

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple clinical trials have reported favorable outcomes after drug-coated balloon therapy for peripheral artery disease in above-the-knee and below-the-knee lesions and in both de novo and in-stent restenosis. However, there are still insufficient data to identify and tackle the risk factors associated with a higher risk of restenosis, which is the primary concern for patients who are treated with an endovascular approach. A modern armamentarium, which includes improved lesion preparation techniques such as plaque modification balloons, mechanical atherectomy, intravascular lithotripsy, and imaging, is crucial for obtaining better long-term clinical outcomes. Moreover, a better understanding of the molecular properties of drug-coated balloons has led to improved devices that could tackle the shortcomings of previous generations. This comprehensive review focuses on drug-coated balloon technology as a tool to treat peripheral artery disease and the effects of the molecular mechanisms involved in preventing vascular restenosis.

Indexed as

Angioplasty, BalloonPeripheral Arterial DiseaseCoated Materials, BiocompatibleDrug-Eluting StentsHumansCoated Materials, Biocompatiblebelow-the-knee (BTK)drug-coated balloon (DCB)femoropopliteal (FP)in-stent restenosis (ISR)paclitaxelperipheral artery disease (PAD)sirolimus

Identifiers

PMID39201436
PMCPMC11354615

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.